Image Credit: Meteoritka / Shutterstock In a recent study published in the Journal of Pediatric Endocrinology and Metabolism , researchers compared the efficacy of metformin and GLP-1based therapies, including GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide, in youth newly diagnosed with type 2 diabetes (T2D)
There was a significant increase from baseline in insulin levels at 60, 90 and 120 minutes in high GLP-1 T2D group ( Figure 3D ), resulting in significantly greater LS-mean increment from baseline in these insulin levels in high GLP-1 compared with low GLP-1 groups ( Figure 3E )
Licensed indication : The same active ingredient may be marketed under different brand names for diabetes versus obesity (e.g., Ozempic vs Wegovy for semaglutide), with different pricing structures
Analytical interference and misleading results Sometimes the number is misleading, or at least not what it appears to be
DO YOU HAVE CONTACT INFORMATION FOR EMPOWER PHARMACY